GlassScriptPhysician profile
Mario C Oliva
NPI 1790824936
$3,202.66
in general payments reported to CMS, 2019-2025
12 companies · $96.12 in 2025
The $96.12 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $139 · 2021: $768 · 2022: $760 · 2023: $608 · 2024: $316 · 2025: $96.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $766.16 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $742.45 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $695.60 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $367.65 | 2019-2024 | Perseris |
| Abbvie INC. | $249.25 | 2022-2025 | |
| Bioxcel Therapeutics, INC. | $89.09 | 2023 | Igalmi |
| Teva Pharmaceuticals USA, INC. | $78.37 | 2023-2024 | Austedo Xr, Uzedy |
| Sunovion Pharmaceuticals INC. | $61.55 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.56 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $47.28 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $28.74 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $24.96 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Oliva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.